Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
|
|
Reuters Health (12.16.02) - Thursday, December 26, 2002
Treatment with tenofovir 300 mg q.d. was added to their antiretroviral regimen, and five patients continued therapy with lamivudine or emtricitabine. By week 12, HBV RNA serum levels declined from a median of 7.95 log10 copies/mL to 4.8 log10 copies/mL. Further treatment until week 24 resulted in an additional decline to 3.6 log10 copies/mL. In two patients, HBV RNA was undetectable by study end. Furthermore, among three subjects in whom HIV RNA was above measurable levels at baseline, the HIV viral load decreased by .7 log10 copies/mL from a median of 3.1 log10 copies/mL.
Tebas and associates note that tenofovir was well tolerated, with only a mild increase of alanine aminotransferase by 17 U/L after 12 weeks of treatment from 53 U/L at baseline.
"The anti-HIV activity of tenofovir, which adefovir lacks, and its excellent tolerability in patients with advanced HIV infection, makes it more attractive for the patient with limited therapeutic options in which the goal of antiretroviral therapy is... to try to lower as much as possible the HIV RNA load," the team wrote. The researchers suggest that combination treatment with lamivudine and tenofovir may augment antiviral activity and increase the "genetic barrier for the development of resistance."
021226
AD022492
Copyright © 2002 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.